Compulsory switch to biosimilars for inflammatory bowel disease

Switching to biosimilars is debated by gastroenterologists in Canada arguing their cost-effectiveness advantages.
Switching to biosimilars is debated by gastroenterologists in Canada arguing their cost-effectiveness advantages.